EBioMedicine · 2025
Preclinical evaluation of long-acting cabotegravir and rilpivirine for HIV post-exposure prophylaxis in a macaque model.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Srinivasan Priya, Zhang Jining, Edwards Tiancheng, Dinh Chuong, Green Ayanna, Little Dawn, Singletary Tyana, Mendoza Maria, Pan Yi, Deyounks Frank, Johnson Ryan, Lipscomb Jonathan, Kourtis Athena P, Heneine Walid, García-Lerma J Gerardo, Smith James M
Аннотация
BACKGROUND: Current guidelines for post-exposure prophylaxis (PEP) recommend 28 days of daily oral antiretroviral drugs. However, low adherence and inadequate regimen completion represent important challenges. We investigated in macaques whether a single injection of the combination of long-acting cabotegravir and rilpivirine (CAB LA/RPV LA) could serve as an effective PEP regimen.
METHODS: Six macaques received a clinically relevant dose of CAB LA/RPV LA 24 h after a single rectal exposure to a high dose of reverse transcriptase simian-human immunodeficiency virus (RT-SHIV). Infection outcome was compared with seven untreated controls.
FINDINGS: CAB LA/RPV LA conferred protection against infection, with two of the six treated macaques becoming infected with RT-SHIV compared with all untreated controls (p = 0.021, Fisher's, exact test). The two breakthrough infections were characterized by early detection of proviral DNA, delayed detection of plasma viral RNA and seroconversion within 3-10 months, and emergence of RPV resistance. The remaining four treated macaques tested negative by multiple serological and molecular assays through 16 months of follow-up. The calculated efficacy of CAB LA/RPV LA was 66.7% (95% CI = -3.4%, 89.3%; p = 0.0571) although the large confidence interval adds uncertainty to the point estimate.
INTERPRETATION: We document protection in macaques by one-time CAB LA/RPV LA PEP under highly stringent modeling conditions. Delayed breakthrough infections highlight potential diagnostic challenges associated with this PEP modality and underscore the need for prolonged follow-up.
FUNDING: This work was funded by CDC intramural funds.
METHODS: Six macaques received a clinically relevant dose of CAB LA/RPV LA 24 h after a single rectal exposure to a high dose of reverse transcriptase simian-human immunodeficiency virus (RT-SHIV). Infection outcome was compared with seven untreated controls.
FINDINGS: CAB LA/RPV LA conferred protection against infection, with two of the six treated macaques becoming infected with RT-SHIV compared with all untreated controls (p = 0.021, Fisher's, exact test). The two breakthrough infections were characterized by early detection of proviral DNA, delayed detection of plasma viral RNA and seroconversion within 3-10 months, and emergence of RPV resistance. The remaining four treated macaques tested negative by multiple serological and molecular assays through 16 months of follow-up. The calculated efficacy of CAB LA/RPV LA was 66.7% (95% CI = -3.4%, 89.3%; p = 0.0571) although the large confidence interval adds uncertainty to the point estimate.
INTERPRETATION: We document protection in macaques by one-time CAB LA/RPV LA PEP under highly stringent modeling conditions. Delayed breakthrough infections highlight potential diagnostic challenges associated with this PEP modality and underscore the need for prolonged follow-up.
FUNDING: This work was funded by CDC intramural funds.